|
On The Fly
| ShowHide Related Items >><< - 07/19/22
- Katapult hires Bork as new Chief Revenue Officer
- 12/05/22
- Nkarta announces updated clinical data on NKX019
- 11/07/22
- Nkarta presents data on NK cell based combination therapies
- 07/25/22
- Nkarta promotes Ralph Brandenberger to Chief Technical Officer
- $1,291.66 /
+5.98 (+0.47%) - 11/16/22
- Markel says Thomas Gayner to become sole CEO on January 1, 2023
- 08/15/22
- Berkshire Hathaway exits Verizon, cuts GM in Q2
JEF Jefferies Financial Group - 12/02/22
- Ebix engages Jefferies as exclusive investment bank
- 11/14/22
- Berkshire Hathaway adds TSMC, exits STORE Capital in Q3
- 11/01/22
- Jefferies Financial Group completes merger with Jefferies Group LLC
- 09/28/22
- Jefferies Financial Group 'increases buyback authorization back to $250M'
- 10/05/22
- Helen of Troy announces restructuring plan, sees annualized savings $75M-$85M
- 09/07/22
- Glaukos rises 19.5%
- 09/07/22
- Glaukos rises 12.2%
- 09/07/22
- Glaukos rises 7.6%
- 09/07/22
- Glaukos announces two iDose TR trials met primary endpoints
- 12/13/22
- Fate Therapeutics announces data on approaches to cancer immunotherapies
- 12/12/22
- GT Biopharma, Fate present preclinical data on dual antigen targeting approach
- 12/11/22
- Fate presents interim data from dose-escalation stage of Phase 1 study of FT819
- 12/11/22
- Fate presents interim clinical data from ongoing Phase 1 stuty of FT576
- 12/20/22
- DLocal announces proposed share purchases by shareholders, management
- 12/20/22
- DLocal board authorizes $100M share buyback plan
- 12/20/22
- DLocal calls short seller allegations 'without merit'
- 11/17/22
- DLocal Ltd trading resumes
- 08/09/22
- Cooper Companies appoints Nicholas Khadder general counsel
- 12/05/22
- Celularity gets Halal certification of advanced cellular therapy, biz model
- 11/10/22
- Celularity presents preclinical data on CYNK-101 at SITC
- 10/06/22
- Celularity names John Haines as CAO, Brad Glover as COO
- 10/03/22
- Celularity appoints Kilcoyne as Chief Medical Officer
- 12/11/22
- Fly Intel: Top five weekend stock stories
- 12/11/22
- Boston Scientific to acquire majority stake of Acotec Scientific
- 11/29/22
- Apollo Endosurgery to be acquired by Boston Scientific for $10.00 per share
- 11/29/22
- Boston Scientific to acquire Apollo Endosurgery for $10.00 per share
- 11/01/22
- MKS Instruments appoints Chang as Senior Vice President, General Manager, Asia
- 10/27/22
- Cassava Sciences appoints Cook as SVP, general counsel
- 08/23/22
- Alcon acquires Aerie Pharmaceuticals for $15.25 per share or $770M
- 07/11/22
- Kala Pharmaceuticals completes sale of EYSUVIS, INVELTYS to Alcon
- 12/22/22 DA Davidson
- Helen of Troy upgraded to Buy from Neutral at DA Davidson
- 11/16/22 Canaccord
- Helen of Troy initiated with Buy on longer term growth at Canaccord
- 11/16/22 Canaccord
- Helen of Troy initiated with a Buy at Canaccord
- 10/06/22 DA Davidson
- Helen of Troy price target lowered to $115 from $175 at DA Davidson
- 12/22/22 DNB Markets
- HMS Networks upgraded with re-rating 'drawing closer' at DNB Markets
- 12/22/22 DNB Markets
- HMS Networks upgraded to Buy from Hold at DNB Markets
- 06/13/22 Nordea
- HMS Networks upgraded to Buy from Hold at Nordea
- 12/22/22 Citi
- Kruk upgraded to Buy on earnings momentum at Citi
- 12/22/22 Citi
- Kruk upgraded to Buy from Neutral at Citi
- 12/22/22 DA Davidson
- Sezzle upgraded to Buy from Neutral at DA Davidson
- 03/01/22 DA Davidson
- Sezzle downgraded to Neutral from Buy at DA Davidson
- 02/28/22 Jefferies
- Zip Co. downgraded to Underperform from Hold at Jefferies
- 12/22/22 Kepler Cheuvreux
- Erste Group Bank upgraded to Buy from Hold at Kepler Cheuvreux
- 12/13/22 Keefe Bruyette
- Erste downgraded to Underperform from Market Perform at Keefe Bruyette
- 11/10/22 JPMorgan
- Erste Group Bank price target raised to EUR 37 from EUR 34 at JPMorgan
- 11/07/22 Deutsche Bank
- Erste Group Bank price target raised to EUR 39 from EUR 38 at Deutsche Bank
- 12/22/22 Oppenheimer
- Fate Therapeutics downgraded to Perform from Outperform at Oppenheimer
- 12/15/22 Goldman Sachs
- Fate Therapeutics initiated with a Sell at Goldman Sachs
- 12/13/22 Truist
- Fate Therapeutics price target lowered to $46 from $51 at Truist
- 12/12/22 Oppenheimer
- Fate Therapeutics price target lowered to $65 from $90 at Oppenheimer
- 12/22/22 Oppenheimer
- Celularity downgraded to Perform from Outperform at Oppenheimer
- 08/25/22 Alliance Global Partners
- Celularity initiated with a Buy at Alliance Global Partners
- 08/23/22 Truist
- Celularity price target lowered to $6 from $10 at Truist
- 06/22/22 H.C. Wainwright
- Celularity initiated with a Buy at H.C. Wainwright
- 12/22/22 Oppenheimer
- Nkarta downgraded to Perform from Outperform at Oppenheimer
- 12/05/22 Oppenheimer
- Nkarta price target lowered to $26 from $36 at Oppenheimer
- 11/16/22 Mizuho
- Nkarta price target lowered to $26 from $81 at Mizuho
- 11/10/22 Oppenheimer
- Nkarta price target lowered to $36 from $50 at Oppenheimer
JEF Jefferies Financial Group - 12/21/22 Keefe Bruyette
- Jefferies downgraded to Market Perform from Outperform at Keefe Bruyette
- 12/21/22 Keefe Bruyette
- Jefferies Financial Group downgraded to Market Perform from Outperform at Keefe Bruyette
- 09/05/22 Keefe Bruyette
- Jefferies upgraded to Outperform from Market Perform at Keefe Bruyette
- 07/18/22 Morgan Stanley
- Jefferies Financial Group price target lowered to $28 from $32 at Morgan Stanley
- 12/22/22 Danske Bank
- Danske downgrades SSAB to Sell on 'falling steel cycle'
- 12/22/22 Danske Bank
- SSAB AB downgraded to Sell from Hold at Danske Bank
- 12/15/22 Morgan Stanley
- SSAB AB price target lowered to SEK 79 from SEK 80 at Morgan Stanley
- 12/14/22 JPMorgan
- SSAB AB downgraded to Underweight from Overweight at JPMorgan
- 12/22/22 Mizuho
- Cooper Companies initiated with a Buy at Mizuho
- 12/09/22 Baird
- Cooper Companies price target lowered to $355 from $370 at Baird
- 12/09/22 Piper Sandler
- Cooper Companies price target lowered to $350 from $355 at Piper Sandler
- 11/30/22 Baird
- Cooper Companies upgraded to Outperform from Neutral at Baird
- 12/22/22 Mizuho
- Alcon initiated with a Buy at Mizuho
- 12/21/22 BTIG
- Alcon price target raised to $78 from $75 at BTIG
- 12/12/22 Citi
- Alcon transferred with a Buy at Citi
- 11/21/22 Credit Suisse
- Alcon price target lowered to CHF 80 from CHF 84 at Credit Suisse
- $1,291.66 /
+5.98 (+0.47%) - 12/22/22 Janney Montgomery Scott
- Janney starts Markel at Buy with $1,550 fair value estimate
- 12/22/22 Janney Montgomery Scott
- Markel initiated with a Buy at Janney Montgomery Scott
- 08/05/22 Truist
- Markel price target lowered to $1,300 from $1,500 at Truist
- 04/28/22 Truist
- Markel price target raised to $1,500 from $1,400 at Truist
- 12/22/22 Mizuho
- Glaukos initiated with a Neutral at Mizuho
- 12/19/22 JPMorgan
- Glaukos upgraded to Neutral from Underweight at JPMorgan
- 12/12/22 Citi
- Citi upgrades Glaukos to Buy on share pullback, new products
- 12/12/22 Citi
- Glaukos upgraded to Buy from Neutral at Citi
- 12/22/22 Mizuho
- Boston Scientific initiated with a Neutral at Mizuho
- 12/20/22 Citi
- Boston Scientific resumed with a Buy at Citi
- 12/08/22 Raymond James
- Boston Scientific price target raised to $54 from $48 at Raymond James
- 12/01/22 Wolfe Research
- Wolfe Research cuts Edwards Lifesciences to Peer Perform on macro, TAVR maturity
- 12/22/22 BofA
- DLocal resumed with a Buy at BofA after allegations formally refuted
- 12/22/22 BofA
- DLocal resumed with a Buy at BofA
- 12/21/22 HSBC
- DLocal price target lowered to $19 from $32 at HSBC
- 12/21/22 New Street
- DLocal downgraded to Neutral from Buy at New Street
- 11/09/22
- Nkarta reports Q3 EPS (58c), consensus (61c)
- 08/11/22
- Nkarta reports Q2 EPS (61c), consensus (60c)
- $1,291.66 /
+5.98 (+0.47%) - 11/01/22
- Markel reports Q3 EPS $3.50, consensus $13.66
- 08/02/22
- Markel reports Q2 diluted EPS ($69.19) vs. $57.02 a year ago
JEF Jefferies Financial Group - 09/28/22
- Jefferies Financial Group reports Q3 adjusted EPS $1.10, consensus 73c
- 06/27/22
- Jefferies Financial Group reports Q2 EPS 45c, consensus 51c
- 10/05/22
- Helen of Troy provides Q3, Q4 outlook
- 10/05/22
- Helen of Troy lowers FY23 non-GAAP EPS view to $9.00-$9.40 from $9.85-$10.35
- 10/05/22
- Helen of Troy reports Q2 adjusted EPS $2.27, consensus $2.21
- 07/07/22
- Helen of Troy sees 2023 consolidated adjusted EPS $9.85-$10.35, consensus $13.17
- 11/02/22
- Glaukos narrows FY22 revenue view to $278M-$280M from $275M-$280M
- 11/02/22
- Glaukos reports Q3 adjusted EPS (45c), consensus (52c)
- 08/03/22
- Glaukos sees FY22 revenue $275M-$280M, consensus $274.4M
- 08/03/22
- Glaukos reports Q2 EPS (83c), consensus (44c)
- 11/03/22
- Fate Therapeutics reports Q3 EPS (86c), consensus (89c)
- 08/03/22
- Fate Therapeutics reports Q2 EPS (79c), consensus (83c)
- 11/14/22
- dLocal reports Q3 EPS 10c, consensus 11c
- 08/22/22
- dLocal reports Q2 EPS 10c, consensus 10c
- 12/08/22
- Cooper Companies sees FY23 EPS $12.30 - $12.60, consensus $13.05
- 12/08/22
- Cooper Companies reports Q4 EPS $2.75, consensus $3.11
- 08/31/22
- Cooper Companies sees Q4 revenue $830M - $850M, consensus $841.43M
- 08/31/22
- Cooper Companies sees Q EPS12.72 - $12.87 , consensus $13.14
- 11/10/22
- Celularity reports Q3 EPS 3c, consensus (26c)
- 08/09/22
- Celularity reports Q2 EPS (32c), consensus (26c)
- 10/26/22
- Boston Scientific cuts FY22 adjusted EPS view to $1.71-$1.74 from $1.74-$1.77
- 10/26/22
- Boston Scientific sees Q4 adjusted EPS 45c-48c, consensus 49c
- 10/26/22
- Boston Scientific reports Q3 EPS 43c, consensus 44c
- 10/25/22
- Notable companies reporting before tomorrow's open
- 11/15/22
- Alcon narrows FY22 EPS view to $2.20-$2.25 from $2.20-$2.30
- 11/15/22
- Alcon reports Q3 core EPS 50c, consensus 48c
- 08/09/22
- Alcon cuts FY22 core EPS view to $2.20-$2.30 from $2.35-$2.45
- 08/09/22
- Alcon reports Q2 core EPS 63c, consensus 49c
|
